Made in Dessau-Roßlau: 25 years of drug production at Oncotec

Oncotec Pharma Produktion GmbH, a company that forms part of the medac Group, was founded in the BioPharmaPark Dessau 25 years ago. The firm has become a major producer of drugs for the treatment of cancer and autoimmune diseases.

In a video message, Minister President Dr. Reiner Haseloff congratulated the company on its anniversary, highlighted the innovative capacity of Oncotec and the entire BioPharmaPark and underlined their importance for Saxony-Anhalt. The regional government reinforced this message with the presence of State Secretary Dr. Jürgen Ude from the State Chancellery and State Secretary Stefanie Pötzsch from the Ministry of Economic Affairs. "Towns like Dessau-Roßlau rely on successful businesses like yours. For this reason among others, I wish Oncotec many more anniversaries in the future," said Dr. Haseloff, Minister President of Saxony-Anhalt. The Mayor of Dessau-Roßlau, Robert Reck, joined in giving the company his good wishes and referred to the importance of the drugs manufactured by Oncotec in treating cancer and autoimmune conditions throughout the world.

Oncotec was founded in February 1997 and production began at the site toward the end of 1999, once the clean rooms and first filling lines had been installed. After 25 years of continuous growth and with a workforce that now numbers 310 people, Oncotec manufactures products for the medac Group and other pharmaceutical companies. These include in particular aseptic liquid cytostatics and innovative specialist products such as highly effective antibody drug conjugates (ADCs).

After taking a look back at the company's history and expressing his pride in what it had achieved, medac Managing Director Frank Generotzky gave the audience an overview of the future projects planned within the group and, in particular, in Dessau-Roßlau. "The medac Group has a lot of plans for Oncotec. The company's future motto will be 'Oncotec goes biotech.'" More than 50 million euros will be invested in maintaining and expanding the site in Dessau-Roßlau in the period up to 2025. This will enable Oncotec to develop and produce additional innovative products and biopharmaceuticals. The drugs that are planned will increase the security of supply of medicines in many countries. They will be used in the fields that the medac Group specializes in, including cancer and complications resulting from stem cell transplants.

A group of nine works entitled "Microscopic Landscapes" by local artist Katrin Zickler, which is an impressive reflection of the company's future plans, was presented by medac Managing Director Jörg Hans to the Oncotec workforce for the company's 25th anniversary. It will be installed in one of the meeting rooms in Dessau-Roßlau.

Source: www.pressebox.de